STAT

Valued for their tech, Silicon Valley digital health companies rely heavily on armies of faraway coaches

In Silicon Valley, digital health companies are valued for their sleek technology. But it's remote health coaches — many of them women, many of them living in America's heartland — that make…

SAN FRANCISCO — Talk to investors about why they like Omada Health, and they point you first to its technology. The startup, they rave, deploys sleek devices to monitor patients with chronic medical conditions; it collects millions of data points on their behavior; and it uses machine learning and other artificial intelligence techniques to automate health reminders and to flag individuals who need more intervention.

It’s a robust operation. It would also fall apart without the likes of DJ Moberly, a “health coach” who spends much of her day exchanging messages with Omada’s diabetes patients from her home in the Houston area — helping them set and stick to goals, encourage them to eat healthy, and offering them tips about controlling their blood sugar levels.

Digital health companies like Omada are now booming businesses. Although their models vary, they all monitor and educate people with chronic medical conditions such as diabetes, hypertension, obesity, and depression — and make money by charging their employers or health plans, with the promise of ultimately lowering medical costs. In just the past few months, leading companies in the sector have gone public

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About AstraZeneca CEO Pay, Alternatives To WuXi And More
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans.…
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FTC Fighting ‘Junk’ Patents, Pfizer Direct-to-consumer Plans, And More
The FTC expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings for 20 different brand-name treatments.

Related Books & Audiobooks